Pulmonary Function Testing Part II

Arthur Jones, EdD, RRT

This Presentation is Approved for 2.0 CRCE Credit Hours

Learning Objectives

- Describe the purposes, physiologic bases devices & methods for diffusing capacity testing
- Describe the purposes, physiologic bases devices & methods for specialized testing regimens
- Describe the purposes, physiologic bases devices & methods for cardiopulmonary exercise testing
- Describe the purposes, physiologic bases devices & methods for metabolic testing
- Interpret results from diffusing capacity tests, specialized tests, cardiopulmonary exercise tests & metabolic tests

Specialized Testing

- > Bronchodilator benefit
- > Bronchial challenge testing
- > Exhaled nitric oxide analysis
- > Preoperative testing
- > Testing for disability

Diffusing Capacity Testing

Diffusing Capacity

- Measures the rate of diffusion of gas across alveolarcapillary membrane
- > Measured as mL (gas)/min/mm Hg (pressure gradient)

See links below to view animation of diffusion

Anatomic Diffusion Pathway

- > Alveolar air
- > Alveolar wall

 - * Alveolar epithelium
 - * Alveolar basement membrane
- > Interstitial space

Anatomic Diffusion Pathway

- Capillary wall
 - * Capillary basement membrane
 - * Capillary endothelium
- > Plasma
- > RBC
 - * Erythrocyte membrane
 - * Intracellular erythrocyte fluid
- > Hemoglobin

See links below for illustration of diffusion pathway

Physical Laws Governing Diffusion

 Henry's law: the amount of gas dissolving in a liquid is proportional to the partial pressure of the gas → derives the solubility coefficient (Ks) of the gas

Physical Laws Governing Diffusion

- > Graham's law: the rate of diffusion through a liquid is
 - * Directly proportional to its Ks

Physical Laws Governing Diffusion

- > Fick's law: gas diffusion is
 - Directly proportional to
 - Alveolar surface area
 - Pressure gradient
 - ❖ Inversely proportional to
 - Alveolar thickness
 - Gram molecular weight of gas

Diffusion Limitations of Gases

- > O₂ can be diffusion &/or perfusion limited
- > CO is diffusion limited, only -> ideal gas to measure diffusing canacity
- \succ Lung diffusing capacity is measured as $\mathrm{DL}_{\mathrm{CO}}$ diffusion in lung of carbon monoxide

Diffusion Tests

- > DL_{co}sb (single breath): most common method
 - * Advantages
 - Simple technique
 - Rapid analysis
 - Disadvantages
 - Sensitive to V/Q mismatching
 - Patient must be capable of breath holding for 10 sec

Diffusion Tests

- DL_{co}rb (rebreathing)
 - * Advantages
 - Most accurate method
 - Least sensitive to V/Q mismatching
 - Can be used during exercise
 - ❖ Disadvantage
 - Requires rapid analyzers
 - Complex calculations

Diffusion Tests

- > DL_{co}ib (intrabreath): analysis during a single exhalation
 - Advantages
 - Does not require breath hold
 - Can be used during exercise
 - Disadvantage
 - Sensitive to VQ mismatch
 - Complex calculations

DL_{co} Testing Indications

- > Evaluation & follow up of parenchymal lung diseases
- > Evaluation & follow-up of emphysema & cystic fibrosis
- > Evaluation of cardiovascular diseases
- Evaluation of pulmonary involvement in systemic inflammatory & collagen vascular diseases

DL_{co} Testing Indications

- Evaluation of the effects of chemotherapy agents or other drugs, e.g. amiodarone
- > Evaluation of pulmonary hemorrhage
- > Evaluation for pneumonectomy or lung reduction surgery
- > Evaluation for disability

Contraindications for Diffusion Tests

- > CO toxicity
- > Severe hypoxemia (O₂ removed during test)
- > Inability to cooperate, e.g. breath holding
- > Large meal or vigorous exercise immediately before the test
- > Smoking within 24 hours of test

DL_{co}sb Equipment

- Spirometer
- > Automatic valve for gas delivery, breath holding, & sampling
- > End-tidal sampler
- > Gas analyzers CO & He
- > Gas mixture
 - ♦ 0.3% CO
 - **∻ 10% He**

DL_{co}sb Procedure

- > Patient performs FVC maneuver
- > Inspires to TLC
- > Holds breath for 9 11 sec
- > Exhales
- > Alveolar sample collected between 750 1000 mL

FYI see links below for AARC CPG on DL_{co} testing

DL_{co}sb Procedure

- Calculation
 - * VA alveolar volume
 - * 60 correction from sec to min

 - PB barometric pressureT breath hold time (sec)

 - ❖ Ln natural logarithm
 ❖ F_{COI} initial fraction of CO
 - ❖ F_{COF} final fraction of CO

 $DL_{CO}sb = VA (STPD) x 60 x Ln FCOI$ (PB - PH₂O) (T) FCOF

DL_{co}sb Acceptability Criteria

- > Test volume must be > 90% previously measured VC
- > End-inspiratory breath hold must be 9 11 sec
- Expiration to RV ≤ 4 sec
- V_D must clear before alveolar sampling
- > Reproducibility criteria: two tests within 10% or 3.0 ml
- > Report: mean value of two tests

DL_{co}sb Predicted Value

- > Normal DL_{co} = 25 ml/min/mm Hg \pm 20%
- > Predicted based on
 - * BSA

 - * Age inverse relationship
- > Interpretation must consider lung volume

Factors Affecting DL_{co}

- > Alveolar surface area
- > V/Q abnormalities
- > Parenchymal thickening, e.g. fibrosis
- > Consolidation
- > Pulmonary capillary pressure
- > RBC, Hb quantities
- > Pulmonary capillary quantity

Conditions With Increased DL_{co}

- Obesity
- > Asthma
- > Left-to-right shunt
- > CHF (without edema)
- > Early polycythemia
- > Large lung volume
- > Exercise
- > Supine position

Conditions With Decreased DL_{co}

- > Decreased surface area
 - ❖ Emphysema
 - Lung resection
- > Increased wall thickness
 - * Hypersensitivity pneumonitis
 - ♦ Fibrosis
 - * Sarcoidosis
- > Decreased carrying capacity anemia

Prognostic Value of DLco

- > Determines when COPD develops into emphysema
- > Predicts complications after surgical resection of lung
- > Predicts mortality in pulmonary arterial hypertension

Bronchodilator Benefit & Bronchial Challenge Testing

Bronchodilator Benefit Testing

- Purpose: determine value of bronchodilators in patient management
- > Indications
 - ❖ Clinical evidence of reactive airways
 - * Wheezing
 - ❖ Dyspnea

Bronchodilator Benefit Testing

- > Preconditions for testing
 - * No short-acting beta agonists or anticholinergics for 4 H
 - * No long-acting beta agonists for 12 H
 - * No long-acting anticholinergic for 24 H
 - * No cromlyn, nedocromil for 24 H
 - * No leukotriene modifiers for 24 H
 - * Maintain inhaled steroids

Bronchodilator Benefit Testing

- > Laboratory requirements
 - * Cooperative patient
 - \div Skilled technologist
 - * Maintained & calibrated equipment
 - * ACLS capabilities
 - * Patient care capabilities in institution

Bronchodilator Benefit Testing

- > Pretests may include
 - \div Spirometry, e.g. FEV₁
 - * sGaw measurement
 - Lung volumes
 - Diffusing capacity

Bronchodilator Benefit Testing

- > Medication administration
 - ♦ Beta agonist: 1 pf Q30s x 4
 - * Ipratropium: 1 pf Q30s x 4
- > Interval before post-testing
 - ❖ Beta agonist: 10 15 min
 - ❖ Ipratropium: 30 min

Bronchodilator Benefit Testing

- Significant improvements
 - * > 12% & 200 mL increase in FEV₁ or FVC
 - ♦ > 30% increase in sGaw

Bronchodilator Benefit Testing

- > Insignificant improvement
 - * May test after time using a medication
 - * May test with a different medication
 - * Check for symptomatic improvement
- > Decreased post-test parameters
 - * Paradoxical drug response
 - ❖ Fatigue

Bronchodilator Benefit Testing

> Calculating % change

 $\frac{\%FEV_1 \text{ change} = \frac{Post FEV_1 - Pre FEV_1}{Pre FEV_1} \times 100}{Pre FEV_1}$

Example: Pre= 1.2L, Post = 1.7L

%FEV₁ change = $\frac{1.7L - 1.2L}{1.2L} \times 100 = 42\%$

Bronchial Challenge Testing

- > Purposes
 - ❖ Detect airway hyperreactivity
 - * Isolate cause of hyperreactivity
 - * Quantify severity of bronchospasm
 - * Assess changes in bronchoreactivity

Bronchial Challenge Testing

> Indications

- * Exclude a diagnosis of airway hyperreactivity
- * Evaluate occupational asthma
- * Assess the severity of bronchospasm
- * Determine the relative risk of developing asthma
- $\boldsymbol{\div}$ Assess response to the rapeutic interventions

Bronchial Challenge Testing

Contraindications

- * Symptoms, e.g. wheeze, cough
- Ventilatory impairment
- * Recent cardiac event or stroke
- ❖ Cerebral aneurysm
- Uncontrolled hypertension
- * Current use of anticholinesterase agent
- * Pregnancy, lactation

Bronchial Challenge Testing

- * Methacholine: parasympathetic stimulator
 - Most common
 - Prepared by pharmacy
- * Histamine: mechanism of action uncertain
- * Exercise: exercise-induced bronchospasm (EIB)

FYI see links below for AARC CPG on methacholine challenge

Bronchial Challenge Testing

Side effects

- * Methacholine
 - Headache
 - Itching
 - Signs & symptoms of severe allergic reaction

- Same as for methacholine
- Flushing

FYI see links below for ATS standards on challenge testing

Bronchial Challenge Testing

Preconditions

- * No bronchodilators, as for bronchodilator benefit test
- * No systemic steroids for 12 hours
- * No cromolyn for 48 hours
- ❖ No antihistamines for 48 hours
- * No exercise, cold air for 2 hours
- * No smoking for 6 hours * No caffeine for 6 hours
- * No beta-blocking agents

Methacholine Challenge Testing

- 5 breath dosimeter
 - Standardizes dose by volume
 - Most precise
- Requires dosimeter
- ♦ 2 minute tidal breathing · Standardizes dose by time
 - Requires only small volume nebulizer

See links below to view dosimeter

Methacholine Challenge Testing

- > Procedure
 - * Baseline mechanics FVC, FEV₁, sGaw, etc.
 - * Inhaled NSS (control dose)
 - ♦ Wait 3 minutes
 - * Repeat measure
 - \div FEV₁ ≤ 80% (of pretest) \rightarrow reactivity \rightarrow stop test
 - \div FEV₁ ≥ 80% (of pretest) \rightarrow non-reactivity \rightarrow proceed

Methacholine Challenge Testing

- > Procedure: 5 breath dosimeter
 - ❖ 5 breaths methacholine 0.0625 to 16 mg/mL
 - ❖ Wait 3 minutes
 - * Repeat, until
 - FEV₁ ≤ 80% control
 - Methacholine concentration = 16 mg/mL

Methacholine Challenge Testing

- > Procedure: 2 min tidal breathing
 - * Administer NSS control dose
 - * Post-test, as for dosimeter
 - Administer methacholine in five quadrupled doses or ten doubled doses from 0.0625 - 16 mg/mL
 - ❖ Wait 3 minutes between
 - * Repeat, until
 - FEV₁ ≤ 80% control
 - Methacholine concentration = 16 mg/mL

Methacholine Challenge Testing

- > Evaluation of results
 - * Provocative dose (PC20)
 - Where FEV₁ decreased by 20%
 - Calculated using last & next-to-last dosages

Histamine Challenge Testing

- Preconditions similar to methacholine challenge, with addition of abstention from antihistamines & H1 receptor antagonists (48 H)
- Procedure similar to methacholine, with ascending doubledosing from 0.03 to 10 mg/mL

Exercise Challenge Testing

- > Purpose: to diagnose exercise-induced bronchospasm (EIB)
- Indicated for patients with normal resting PFTs who report dyspnea on exertion

Preconditions * Withhold activity & medications, as for methacholine challenge * Pretest ECG * Pretest FEV₁ ≥ 65% predicted * Room temperature < 25 °C * Relative humidity ≤ 50%

Exhaled Nitric Oxide Analysis

Nitric Oxide (NO) Physiology No: multipurpose molecule that mediates many physiologic processes, including Smooth muscle relaxation Platelet inhibition Neurotransmission Apoptosis (programmed cell death) Immune regulation

Nitric Oxide (NO) Physiology

- NO synthesis catalyzed by NO synthases
 - ❖ Endothelial
 - ❖ Neural
 - $\boldsymbol{\div}$ Induced by inflammatory cytokines, e.g. as in asthma

Nitric Oxide (NO) Physiology

- > eNO is a noninvasive marker for airway inflammation, that
 - * Increases in patients with atopic (allergic) asthma
 - Decreases in asthmatic subjects treated with inhaled corticosteroids
 - * Correlates with the sputum eosinophil quantity

Diagnostic Utility of eNO

- FeNO for lung transplant patient may detect infection, rejection, & bronchiolitis obliterans
- > FeNO reflects degree of asthma control by steroids
- Asthma diagnosis based on FeNO is less expensive than standard methods

FYI see links below for article with asthma management algorithm using FeNO

Diagnostic Utility of eNO

- > Smoking does NOT devalue FeNO in asthma control
- > FeNO analysis is NOT validated for acute exacerbations
- > FeNO reflects inflammation, NOT bronchospasm

FeNO Analysis

- > Chemiluminescent analyzer
- > FeNO reported in parts per billion (ppb) @ L/sec
- > Measurement techniques
 - * Off-line: sample collected in device for later analysis
 - $\boldsymbol{\diamondsuit}$ Online: sample collected at the mouth
 - * Nasal sampling

FYI see links below for information on chemiluminescent analyzer


FeNO Analysis

- > Off-line sampling
 - Patient inhales to TLC from NO scrubber or reservoir of NO-free gas
 - * Exhales VC with 5 cm H₂O resistance @ 0.35 L/sec
 - * Sample collected in mylar balloon
 - * Analysis within 12 H

FeNO Analysis > Online sampling \$ Patient inhales to TLC through scrubber \$ Patient exhales VC into analyzer at controlled resistance



FeNO Analysis See links below to view GE Sievers 2801™ FeNO analyzer & Eco Medics CLD88™ FeNO analyzer



Preoperative Testing

Preoperative Testing Purposes: for abdominal, chest procedures, to Assess risk (operability?) Predict postoperative function Plan postoperative patient care

Preoperative Testing

- Postoperative function may improve in some lung resection cases
- > Function testing does not predict postoperative quality-oflife

FYI see links below for article on post-op QOL

Preoperative Testing

- > Indications
 - History of smoking (> 20 pk/yrs)
 - * Active pulmonary symptoms
 - * Abnormal physical examination
- > Conditional indications
 - * Evidence of pulmonary infection
 - * Morbid obesity
 - * Debilitation, malnourishment

Preoperative Tests

- \succ Lung volumes, including $\mbox{V}_{\mbox{\scriptsize TG}}$ for pulmonary resection for emphysema
- > Spirometry with maximal bronchodilation
- \succ Perfusion, V/Q scans, contrast MRI: can be used to estimate postoperative FEV $_1$ for lung resections
- Measurement of FEV₁ on first day post-op is good predictor of morbidity

Preoperative Tests

- DLco: lung resection
- > Arterial blood gases: patients with documented pulmonary disease
- > Bronchodilator benefit: patients with obstructive disease
- > Exercise stress testing
 - * Cardiac surgery
 - * Borderline predicted post-op lung function

Interpretation Guidelines


Test	Increased risk
FVC	<50% pred
FEV1	<2.0 L or <50% pred
MVV	NA
PaCO2	NA
DLCO	<60% pred
VO2 _{MAX} (O2 uptake)	<20 mL/kg/min

Interpretation Guidelines

Test	Increased risk	Significant risk
FVC	<50% pred	<1.5 L
FEV1	<2.0 L or <50% pred	<1.0 L
MVV	NA	<50% pred
PaCO2	NA	>45 mm Hg
DLCO	<60% pred	
VO2 _{sax} (O2 uptake)	<20 mL/kg/min	<10 mL/kg/min







Disability Evaluation > Blood gases & impairment \$\display PaO_2 < 55 \text{ mm Hg on 0.21 OR} \$\display PaO_2 < 60 \text{ mm Hg on 0.21 AND} Pulmonary hypertension OR Cor pulmonale OR Erythrocytosis OR Hypoxemia worsened with mild exercise

Disability Evaluation

- > Additional factors to consider
 - Subject cooperation (malingering)
 - * Hx of emergency treatment for asthma
 - ❖ Failure to receive appropriate care
 - Deconditioning (couch potato)
 - Coexisting disorders
 - * Impairment that is difficult to measure

Cardiopulmonary Exercise Testing (CPET)

Indications for Exercise Testing

- Diagnose cardiopulmonary disorders, often to distinguish between cardiac vs. pulmonary dx
- Measure impairment (disability)
- > Evaluate therapy
- > Develop exercise prescriptions (rehabilitation)
- > Assess fitness for occupations, physical activities, etc.

Contraindications for Exercise Testing

- Limiting neurologic, neuromuscular, or orthopedic conditions
- > Pulmonary contraindications

 - ❖ Room air PaO₂ < 40 mm Hg</p>
 - ♦ PaCO₂ > 70 mm Hg
 - * Severe pulmonary hypertension

Contraindications for Exercise Testing

- > Cardiovascular conditions
 - * Acute pericarditis
 - ♦ CHF
 - ♦ Recent MI
 - * Heart block: 2nd or 3rd degree
 - * Tachydysrhythmias
 - * Uncontrolled hypertension
 - ♦ Unstable angina
 - * Recent systemic or pulmonary embolus
 - * Aortic stenosis

Pulmonary Changes With Exercise

- > TV increases early
- > Respiratory rate increases late
- > Vd/Vt decreases
- > V/Q equalizes
- > Capillary transit time decreases increased velocity of blood

Cardiovascular Changes With Exercise

- > Cardiac output
 - ❖ Stroke volume: increases to maximum value❖ HR max
 - Reached at exhaustion
 - HR max = 220 age

Cardiovascular Changes With Exercise

- Blood pressure
 - ❖ Systolic increases
 - * Diastolic remains stable
 - ❖ Pulse pressure increases
- Distribution of circulation: increased perfusion of musculature & skin
- > O₂ pulse (mL O₂ per heart beat): increases
 - * O₂ pulse = VO₂ / HR
 - * Index of stroke volume

Metabolic Changes With Exercise

- > O₂ consumption
 - * Normal VO₂ = 250 ml/min (3.5 ml/kg BW)
 - VO_2 max = greatest O_2 consumption a person can reach
 - ❖ Normal VO₂ max = 7 times resting value
 - $\boldsymbol{\div}$ METS: unit relating $\text{VO}_2\,\text{max}$ to resting value

Metabolic Changes With Exercise

 $METS = VO_2 max$ 3.5 ml/min x BW

Normal METS (sedentary) = 7

Normal $VO_2 \max = (7 \times 3.5) = 24.5 \text{ ml/min/kg}$

Metabolic Changes With Exercise

- > 1 MET: rest
- > 4 METS: housework, bowling
- > 6 METS: farming, tennis
- > 8 METS: heavy manual labor, skiing
- > 12 METS: hockey
- > 18 METS: rowing, swimming

Metabolic Changes With Exercise

- CO₂ production increases proportional to VO₂, up to anaerobic threshold, then increases at faster rate to buffer lactic acid
- > RQ (VCO₂ / VO₂): increases to 1.0, just before exhaustion
- > Ph: becomes acid after anaerobic threshold is reached

Exercise Limits

- Anaerobic threshold (AT)
 - Point at which anaerobic metabolism begins in response to exercise
 - \div Greatest work level, or O_2 consumption that can be produced before lactic acid is produced
- Physical exhaustion normally occurs shortly after passing the AT

Causes of Exhaustion

- \rightarrow Work to eliminate CO $_2$ becomes excessive ventilation produces more CO $_2$ than excretion
- > Cardiovascular system cannot oxygenate tissues
- > Depletion of glycogen energy need
- Excessive perception of symptoms, e.g. dyspnea, dizziness, chest tightness

General Types of Tests

- Tests to evaluate fitness
- > Tests to evaluate effects of exercise on oxygenation
- > Tests to evaluate exercise tolerance (stress tests)

Testing for General Fitness

- > 12 minute walking distance
 - * Subject walks as far & fast as possible for 12 min
 - * Distance walked reflects fitness

Testing for General Fitness

- > Harvard step test
 - * Subject steps up & down platform for five minutes

Up next: Video on step test

Testing to Evaluate Desaturation

- > Purposes
 - * To detect diffusion defect
 - $\ensuremath{ \raisebox{.4ex}{$\raisebox{.4ex}{}}}}}}}}}}}}}}}}}}}$
- $> \, {
 m If pre-exercise SaO_2 < 90, then supplemental O_2} \, {
 m is needed} \, \, {
 m during test}$

Testing to Evaluate Desaturation

- > Subject exercises on treadmill or ergometer for 6 min
 - * Parameters monitored
 - Pre-exercise SaO₂, SpO₂: correlate values
 - Exercise SpO₂
 - ECG
 - Blood pressure

Testing to Evaluate Desaturation

- > Results
 - ♦ Normally, SpO₂ increases due to improved VQ matching
 - **♦** SpO₂ > 90% after 6 minutes → no desaturation
 - * SpO₂ decreased by 5% or drops to less than 85%, test terminated & results are positive for desaturation & likely diffusion defect

Types of Exercise Tolerance Tests

- Constant work
- > Incremental work: more common
 - * Staged increments stepwise
 - $\ \, \mathbf{ \ \, ? \ \, } \ \, \mathbf{ Ramp \ \, increments constant } \\$

Exercise Testing Equipment

- > Treadmill
 - * Advantages
 - Familiar exercise
 - Typical activity (ADL)
 - Disadvantages
 - Subject weight is a factor
 - Large, heavy, noisy
 - Expensive
 - Safety issues

FYI see links below for video on treadmill misadventures

Exercise Testing Equipment

- > Bicycle ergometer
 - Advantages
 - Workload unaffected by weight
 - Workload precisely measured
 - Small, portable
 - Inexpensive
 - Safer than treadmill

Exercise Testing Equipment

- > Bicycle ergometer
 - Disadvantages
 - Unfamiliar exercise
 - Not ADL
 - * Yields results slightly different from treadmill

FYI see links below for article on exercise testing in clinical practice

Exercise Testing Equipment

- > Gas volume measurement device
- > Gas collection, mixing devices
- > Gas analyzers: O₂, CO₂
- Pulse oximeter
- > ECG monitor: filtered for motion artifact
- > Blood pressure monitor
- > Crash cart

Exercise Tolerance Testing

- > Preparation of subject
 - ❖ Comfortable clothes
 - ❖ No meal within 2 H
 - * No smoking, coffee within 2 H
 - ***** Continue medications as prescribed
 - $\boldsymbol{\div}$ Orient to equipment & procedures include hand signals

Exercise Tolerance Testing

- > Preliminary assessment
 - ♦ Hx & Px
 - * 12 lead ECG
 - ♦ PFTs
 - Spirometry
 - MVV
 - DL_{co}

Exercise Tolerance Testing

- > Obtain resting values
 - * Arterial blood gas
 - * Lactate (in some labs)
 - ♦ SpO₂: correlate with SaO₂
 - ♦ TV, f, VE
 - * PetCO₂, PetO₂
 - ♦ HR, BP, ECG pattern

Exercise Tolerance Testing

- > Practice at minimal work level: check monitors & equipment
- > Exercise: increase workload
 - * Intervals
 - ❖ Ramp
- Monitor continuously or sample at each work level depends on system


See links below for image of exercise testing


Exercise Tolerance Testing


- > Indicators to stop test
 - * Exhaustion: desired endpoint
 - * CNS symptoms: vertigo, etc.
 - * Nausea, vomiting
 - * Chest pain, SOB
 - ❖ SpO₂ drop > 5%
 - * Dysrhythmias: frequent PVCs, etc.
 - ♦ PSYS > 250 mm Hg
 - * Equipment failure

Indicators of Maximal Effort VO₂ max ≥ 85% pred VE max ≥ 70% MVV HR max > 90% pred Blood lactate ≥ 4 mM/L

Data Reported > VE, TV, f > VO₂ = (FiO₂ x VI) - (FEO₂ x VE) > METS = VO₂ max/3.5 ml/min x BW > CO₂ production = (FECO₂ - FiCO₂) VE > O₂ pulse = VO₂ x 1000/HR > Vd/Vt = (PaCO₂ - PetCO₂)/PaCO₂ > R = VO₂/VCO₂







Interpretation of Abnormal Results				
Parameters at Maximal Exercise	Poor Conditioning	Pulmonary disorders	Cardiovascular disorders	
VO2max	Low	Low	Low	
METS	Low	Low	Low	
VEmax/MVV	Low	High	Low	
SpO2 SaO2	Nomal	Low	Nomal	
Vd/Vt	Normal	Normal- High	Normal	
HRmax/worldoad	High	Nomal	Hìgh	
02 pulse	Normal	Normal	Low	



Purposes of Metabolic Testing Measure nutritional requirements Measure relative metabolic contributions of Carbohydrates Lipids Protein

Rationale for Bedside Assessment Critically ill patients have highly variable metabolic needs Patients often are NPO & receive all nourishment via total parenteral nutrition (TPN)

> COPD > Multiple trauma > Acute pancreatitis > Organ transplant patients > Morbid obesity > Hyper or hypo-metabolism > Prolonged mechanical ventilation & NPO status (weaning)

Complications of Malnourishment

- > Impaired function of all organ systems
- > Immunocompromise
- > Delayed wound healing
- > Increased ventilatory load due to
 - * Increased oxygen demand
 - ❖ Increased CO₂ production

FYI see links below for article on calorimetry & weaning

Methods for Nutritiional Assessment

- > Anthropometric
 - * Skin fold thickness
 - * Arm circumference
- > Laboratory assessment serum proteins
- > Calorimetry

Calorimetry Methods

- Direct: complete enclosure of body & measurement of heat production
- Indirect: uses VO₂, VCO₂, VE to calculate energy expenditure
 - ❖ Closed circuit method
 - * Open circuit method

FYI see links below for AARC CPG on indirect calorimetry during mechanical ventilation

Closed Circuit Method

- > Subject rebreathes in closed system
- > CO₂ is absorbed
- > $\rm O_2$ measured volumetrically with spirometer \Rightarrow VI VE = $\rm VO_2$
- > Not compatible with current ventilators

Open Circuit Method

- > Hood or canopy for spontaneously breathing patients
- > Ventilator attaches at airway
- > Measured parameters
 - ♦ FiO₂ & FEO₂
 - * FiCO₂ & FECO₂
 - ♦ VE

See links below to view open circuit calorimetry with hood

Open Circuit Method

> Calorimeters

See links below to view

Test Administration

- > Patient preparation
 - * Avoid stimulants prior to test
 - * Fast for 2 4 H, if PO
 - * Continuous feedings, if NPO
 - No ventilator adjustments immediately before testing (within 90 min)
- Neutral thermal environment must be maintained no thermal stress
- > Measurements made during steady state

Calculated Parameters

- > Resting energy expenditure (REE)
 - ♦ VO₂
 - + VCO
 - * UN (urinary N₂) not critical to test
- > Caloric equivalents for
 - Carbohydrates
 - Lipids
 - ❖ Protein
- Respiratory quotient (RQ)

Significance of Results

- > RQ < 0.67 or RQ > 1.3 → error
- > RQ < 0.7 → starvation or ketosis
- > RQs for predominant substrate
 - ❖ Carbohydrates = 1.0

 - ❖ Protein = 0.82
- > REE > caloric intake → underfeeding
- REE < caloric intake → overfeeding</p>

Summary & Review

- Diffusing capacity

 - Pathophysiology

 - * Normal DL_{co}sb = 25 mL/min/mm Hg
 - ❖ Increased with obesity, asthma
 - * Decreased with emphysema, fibrosis

Summary & Review

- > Bronchodilator benefit: before & after bronchodilator tests
 - * Indications
 - Preconditions
 - *** Procedure**
 - ❖ Significant improvement
 - 12% ${\rm FEV_1}$ increase & 200 mL ${\rm FEV_1}$ or FVC increase
 - 30% sGAW increase

Summary & Review

- Bronchial challenge testing: detects & measures airway reactivity
 - * Provocative agents: methacholine, histamine, or exercise
 - * Preconditions, procedure
 - * Significant results
 - \bullet PC20: dose where FEV_1 decreased by 20%
 - Decrease in mechanics produced by exercise

Summary & Review

- Exhaled nitric oxide (eNO) analysis
 - Production of NO increased by allergic asthma noninvasive marker for inflammation
 - **❖ Sampled on-line or off-line**
 - ♦ Normals = \leq 35 ppb for adults & \leq 25 ppb for children
 - ❖ Increased → eosinophilic inflammation
 - ❖ Decreased trend → effective steroid therapy

Summary & Review

- Preoperative testing: for risk, postoperative function, & care planning
 - Indications, e.g. smoking history
 - $\boldsymbol{\div}$ Tests, e.g. spirometry, DL_{CO} , ABGs, imaging, CPET
 - ♦ Increased risk, e.g. FVC \leq 50% pred.
 - ♦ Significant risk, e.g. FVC $\leq 1.5 L$

Summary & Review

- Testing for disability: to detect & measure physical impairment
 - \div Battery: Hx & Px, spirometry, DL $_{\!\text{CO}}$ ABGs, CPET
 - ❖ Obstruction: FEV₁
 - * Restriction: FVC
 - * Asthma: FEV₁, episodes
 - Oxygenation: PaO₂, comorbidities, e.g. pulmonary hypertension

Summary & Review

- Cardiopulmonary exercise testing
 - Purposes
 - Diagnose cardiopulmonary disease
 - Distinguish pulmonary vs. cardiac dx
 - Assess fitness
 - Develop exercise prescriptions
 - Normal changes with exercise: cardiac, pulmonary, metabolic
 - * Parameters: VO₂ max, METS, O₂ pulse, HR max

Summary & Review

- > Cardiopulmonary exercise testing
 - ❖ Types of tests: fitness, evaluation of oxygenation, stress tests
 - * Fitness: Harvard step, 12 min walking
 - * Oxygenation: 6 min exercise with continuous SpO₂

Summary & Review

- > Cardiopulmonary exercise testing
 - Stress testing: treadmill or bicycle ergometer exercise to exhaustion
 - * Monitors
 - Expired O₂ & CO₂
 - SpO₂
 - TV, f, VE • HR, BP, ECG
 - Lactate (optional)

Summary & Review

- > Cardiopulmonary exercise testing
 - ❖ Indicators of maximal effort, e.g. HR max > 90% pred.
 - Normal responses: oxygenation stable or improved, O₂ pulse increases

Summary & Review

- > Cardiopulmonary exercise testing
 - ❖ Indicators of maximal effort, e.g. HR max > 90% pred.
 - Normal responses: oxygenation stable or improved, O₂ pulse increases
 - Interpretation
 - Poor conditioning: normal pulmonary parameters & \mathbf{O}_2 pulse
 - Pulmonary disease: low pulmonary parameters
 - Cardiac disease: low O2 pulse

Summary & Review

- Metabolic testing: to measure nutritional requirements & determine metabolic contributions
 - $\boldsymbol{\div}$ Indications, e.g. prolonged mechanical ventilation
 - * Calorimetry methods
 - Direct vs. indirect
 - · Indirect: closed vs. open circuits

Summary & Review

- Metabolic testing
 - * Calorimeter attached to airway & measures
 - FiO₂, FEO₂
 - FiCO₂, FECO₂
 - VE
 - * Calculated values
 - Resting energy expenditure (REE)
 - Caloric equivalents
 - Respiratory quotient (RQ)

Summary & Review

> Results may detect

- ❖ Measurement error
- * Starvation or ketosis
- * Contributions from carbohydrates, lipids, proteins
- Underfeeding
- Overfeeding

References

- Ruppel GL. Manual of Pulmonary Function Testing, 9th Ed. Chaps. 5, 7, 9. 2009 Mosby-Elsevier; St. Louis.
- Madama VC. Pulmonary function testing and cardiopulmonary stress testing 2nd ed. Chaps. 6, 8, 14, 15. 1998; Delmar; Albany.
- Brunelli A, Refai MA, Salati M, Sabbatini A, MorganHughes NJ, Rocco G. Carbon monoxide lung diffusion capacity improves risk stratification in patients without airflow limitation: evidence for systematic measurement before lung resection. Eur J Cardiothorac Surg. 2006 Apr;29(4):567-70.

References

- Saydain G, Beck KC, Decker PA, Cowl CT, Scanlon PD. Clinical significance of elevated diffusing capacity. Chest. 2004 Feb; 125(2):446-52.
- Bobbio A, Chetta A, Carbognani P, Internullo E, Verduri A, Sansebastiano G, Rusca M, Olivieri D. Changes in pulmonary function test and cardiopulmonary exercise capacity in COPD patients after lobar pulmonary resection. Eur J Cardiothorac Surg. 2005 Nov;28(5):754-8.
- Lamberto C, Nunes H, Le Toumelin P, Duperron F, Valeyre D, Clerici C. Membrane and capillary blood components of diffusion capacity of the lung for carbon monoxide in pulmonary sarcoidosis: relation to exercise gas exchange. Chest. 2004 Jun;125(6):2061-8.

References

- Lee JS, Ra SW, Chae EJ, Seo JB, Lim SY, Kim TH, Lee SD, Oh YM. Validation of the Lower Limit of normal Diffusing Capacity for Detecting Emphysema. Respiration. 2010 Jan 20
- Wang JS. Relationship of carbon monoxide pulmonary diffusing capacity to postoperative cardiopulmonary complications in patients undergoing pneumonectomy. Kaohsiung J Med Sci. 2003 Sep;19(9):437-46.
- Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M. Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant. 2010 Feb;29(2):181-7. Epub 2009 Sep 26.

References

- Rodway GW, Choi J, Hoffman LA, Sethi JM. Exhaled nitric oxide in the diagnosis and management of asthma: clinical implications. Chron Respir Dis. 2009;6(1):19-29.
- Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. Allergy. 2009 Mar;64(3):431-8. Epub 2009 Jan 29.
- Kwok MY, Walsh-Kelly CM, Gorelick MH. The role of exhaled nitric oxide in evaluation of acute asthma in a pediatric emergency department. Acad Emerg Med. 2009 Jan;16(1):21-8. Epub 2008 Nov 27.

References

- Hewitt RS, Modrich CM, Cowan JO, Herbison GP, Taylor DR. Outcomes using exhaled nitric oxide measurements as an adjunct to primary care asthma management. Prim Care Respir J. 2009;18(4):320-7.
- Ferguson MK, Gaissert HA, Grab JD, Sheng S. Pulmonary complications after lung resection in the absence of chronic obstructive pulmonary disease: the predictive role of diffusing capacity. J Thorac Cardiovasc Surg. 2009 Dec;138(6):1297-302.
- Sue DY, Wasserman K. Impact of integrative cardiopulmonary exercise testing on clinical decision making. Chest. 1991 Apr;99(4):981-92.

References

- Chetta A, Tzani P, Marangio E, Carbognani P, Bobbio A, Olivieri D. Respiratory effects of surgery and pulmonary function testing in the preoperative evaluation. Acta Biomed. 2006 Aug;77(2):69-74.
- Milani RV, Lavie CJ, Mehra MR, Ventura HO. Understanding the basics of cardiopulmonary exercise testing. Mayo Clin Proc. 2006;81(12):1603-11.
- ERS Task Force, Palange P, Ward SA, Carlsen KH, Casaburi R, Gallagher CG, Gosselink R, O'Donnell DE, Puente-Maestu L, Schols AM, Singh S, Whipp BJ. Recommendations on the use of exercise testing in clinical practice. Eur Respir J. 2007;29(1):185-209.

References

- Cote CG, Pinto-Plata V, Kasprzyk K, Dordelly LJ, Celli BR. The 6-min walk distance, peak oxygen uptake, and mortality in COPD. Chest. 2007;132(6):1778-85.
- American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003 Jan 15;167(2):211-77. Review. Erratum in: Am J Respir Crit Care Med. 2003 May 15;1451-2.
- Rasekaba T, Lee AL, Naughton MT, Williams TJ, Holland AE. The six-minute walk test: a useful metric for the cardiopulmonary patient. Intern Med J. 2009 Aug;39(8):495-501.

References

- Benzo RP, Sciurba FC. Oxygen Consumption, Shuttle Walking Test and the Evaluation of Lung Resection. Respiration. 2009 Aug 11.
- Benzo RP, Paramesh S, Patel SA, Slivka WA, Sciurba FC.
 Optimal protocol selection for cardiopulmonary exercise testing in severe COPD. Chest. 2007 Nov;132(5):1500-5.
- Varela, et al. Measured FEV1 in the first postoperative day, and not ppoFEV1, is the best predictor of cardiorespiratory morbidity after lung resection. Eur J Cardiothorac Surg 2007 31: 518-521

References

- Ferrazza AM, Martolini D, Valli G, Palange P. Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases. Respiration 2009;77(1):3-17.
- Pan AM, Stiell IG, Clement CM, Acheson J, Aaron SD. Feasibility of a structured 3-minute walk test as a clinical decision tool for patients presenting to the emergency department with acute dyspnoea. Emerg Med J. 2009 Apr;26(4):278-82.
- Buschmann HC, Petermann W. Differential diagnosis of restrictive lung diseases: utility of cardiopulmonary exercise testing. Pneumologie. 2010 Jan;64(1):28-36.